Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

Nikkei ends lower as rising COVID-19 infections sap risk appetite

Published 12/15/2020, 02:37 PM
Updated 12/15/2020, 02:40 PM
JP225
-
TOPX
-
7012
-
9202
-
9201
-
3632
-
2931
-
3038
-
5491
-
3765
-

TOKYO, Dec 15 (Reuters) - Japanese shares ended weaker on
Tuesday as rising COVID-19 infections sapped investors appetite
for risk assets and forced the government to suspend its
domestic tourism promotion campaign, hitting airlines and other
travel-related stocks.
The Nikkei share average .N225 dropped 0.17% to 26,687.84.
The broader Topix .TOPX lost 0.47% to 1,782.05, with decliners
outnumbering advancers by a ratio of 3 to 2.
Investors are locking in profit from recent gains, ahead of
policy announcements later this week by the U.S. Federal Reserve
and the Bank of Japan.
Concerns about increasing COVID-19 infections and lockdowns
around the world overshadowed optimism over the rollout of
coronavirus vaccinations. MKTS/GLOB
Tourism-related shares took a hit after Japanese Prime
Minister Yoshihide Suga said the travel subsidy programme dubbed
"Go To Travel" would be suspended nationwide around the New Year
to contain mounting COVID-19 cases.
ANA Holdings 9202.T lost 7.9% after investors flipped some
of its newly issued stocks while rival JAL 9201.T lost 3.4%.
L4N2IV0HD
On the other hand, some game-related shares rode higher as
the worsening domestic outbreak is seen as boosting demand for
game products.
GungHo Online Entertainment 3765.T added 0.5% while Gree
3632.T gained 2.7%.
Clean energy is becoming another hot theme, with Kawasaki
Heavy 7012.T rising 5.7%, extending gains on its announcement
earlier in the week that it has signed a memorandum of
understanding (MoU) with Australian miner Fortescue Metals Group
Ltd FMG.AX to develop a supply chain of "green" hydrogen.

Nippon Kinzoku 5491.T rose by daily limit of 28% on
speculation of surge in demand for its product for injection
needles as COVID-19 vaccinations start globally.
Euglena 2931.T gained 2.5% after the bio-tech firm said it
is considering buying health product maker Q'say.
Kobe Bussan 3038.T dropped 7.9% after its earnings fell
short of market expectations.


Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.